Citizens reiterates Cellectis stock rating on CAR-T progress
#Cellectis #Citizens #stock rating #CAR-T #cell therapy #biotech #investment
📌 Key Takeaways
- Citizens reaffirms its stock rating for Cellectis, indicating confidence in the company's outlook.
- The reiteration is based on progress in Cellectis's CAR-T cell therapy development programs.
- Positive developments in CAR-T research are likely driving the maintained rating.
- The news highlights ongoing investor and analyst interest in biotech advancements.
🏷️ Themes
Biotechnology, Finance
Entity Intersection Graph
No entity connections available yet for this article.